Indiana Trust & Investment Management CO continued to hold its stake in shares of CVS Health Corporation (NYSE:CVS) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,744 shares of the pharmacy operator’s stock at the end of the second quarter. Indiana Trust & Investment Management CO’s holdings in CVS Health Corporation were worth $1,589,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Mercer Capital Advisers Inc. acquired a new position in shares of CVS Health Corporation in the 1st quarter valued at $118,000. SRS Capital Advisors Inc. grew its holdings in shares of CVS Health Corporation by 48.2% in the 1st quarter. SRS Capital Advisors Inc. now owns 2,256 shares of the pharmacy operator’s stock valued at $177,000 after buying an additional 734 shares during the period. Cue Financial Group Inc. grew its holdings in shares of CVS Health Corporation by 3.6% in the 1st quarter. Cue Financial Group Inc. now owns 2,708 shares of the pharmacy operator’s stock valued at $213,000 after buying an additional 95 shares during the period. Pettee Investors Inc. acquired a new position in shares of CVS Health Corporation in the 1st quarter valued at $214,000. Finally, Diversified Trust Co acquired a new position in shares of CVS Health Corporation in the 1st quarter valued at $229,000. 81.55% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Indiana Trust & Investment Management CO Has $1,589,000 Stake in CVS Health Corporation (CVS)” was originally reported by Daily Political and is the property of of Daily Political. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.dailypolitical.com/2017/09/14/indiana-trust-investment-management-co-has-1589000-stake-in-cvs-health-corporation-cvs.html.

Shares of CVS Health Corporation (CVS) traded down 0.07% during midday trading on Thursday, hitting $83.02. 1,889,754 shares of the stock were exchanged. The stock has a market capitalization of $84.40 billion, a price-to-earnings ratio of 16.54 and a beta of 0.92. The firm’s 50 day moving average is $78.56 and its 200-day moving average is $78.91. CVS Health Corporation has a 1-year low of $69.30 and a 1-year high of $91.13.

CVS Health Corporation (NYSE:CVS) last issued its quarterly earnings data on Tuesday, August 8th. The pharmacy operator reported $1.33 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.31 by $0.02. The firm had revenue of $45.69 billion during the quarter, compared to analysts’ expectations of $45.36 billion. CVS Health Corporation had a net margin of 2.93% and a return on equity of 17.47%. The business’s revenue was up 4.5% on a year-over-year basis. During the same period last year, the company earned $1.32 earnings per share. On average, analysts predict that CVS Health Corporation will post $5.88 EPS for the current year.

CVS has been the subject of a number of research analyst reports. Cowen and Company reaffirmed an “outperform” rating and issued a $86.00 target price on shares of CVS Health Corporation in a research note on Tuesday, June 13th. BidaskClub raised shares of CVS Health Corporation from a “sell” rating to a “hold” rating in a research note on Wednesday, August 2nd. Citigroup Inc. reduced their target price on shares of CVS Health Corporation from $88.00 to $87.00 and set a “neutral” rating for the company in a research note on Thursday, August 17th. Leerink Swann set a $90.00 target price on shares of CVS Health Corporation and gave the stock a “buy” rating in a research note on Tuesday, June 27th. Finally, Wolfe Research lowered shares of CVS Health Corporation from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $89.00 to $82.00 in a research note on Monday, August 14th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $90.14.

In other news, EVP Thomas M. Moriarty sold 90,267 shares of CVS Health Corporation stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $79.61, for a total transaction of $7,186,155.87. Following the completion of the transaction, the executive vice president now directly owns 70,102 shares in the company, valued at $5,580,820.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO David M. Denton sold 237,078 shares of CVS Health Corporation stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $79.65, for a total transaction of $18,883,262.70. Following the transaction, the chief financial officer now owns 141,096 shares of the company’s stock, valued at $11,238,296.40. The disclosure for this sale can be found here. Insiders have sold 370,510 shares of company stock valued at $29,460,266 over the last quarter. Corporate insiders own 0.61% of the company’s stock.

CVS Health Corporation Company Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Institutional Ownership by Quarter for CVS Health Corporation (NYSE:CVS)

Receive News & Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related companies with MarketBeat.com's FREE daily email newsletter.